Cargando…

Treatment, Survival, and Prognosis of Advanced-Stage Natural Killer/T-Cell Lymphoma: An Analysis From the China Lymphoma Collaborative Group

Patients with advanced-stage natural killer/T-cell lymphoma (NKTCL) usually have a poor prognosis. However, there is limited data of comprehensive analysis on this particular patient population due to the rarity of the disease. The present study aimed to investigate the treatment models, survival ou...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Weiping, Yang, Yong, Qi, Shunan, Wang, Ying, He, Xia, Zhang, Liling, Qu, Baolin, Qian, Liting, Hou, Xiaorong, Qiao, Xueying, Wang, Hua, Li, Gaofeng, Zhang, Yujing, Zhu, Yuan, Cao, Jianzhong, Wu, Junxin, Wu, Tao, Zhu, Suyu, Shi, Mei, Xu, Liming, Su, Hang, Lin, Ningjing, Zhu, Jun, Li, Yexiong, Song, Yuqin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7945040/
https://www.ncbi.nlm.nih.gov/pubmed/33718104
http://dx.doi.org/10.3389/fonc.2020.583050
_version_ 1783662786079883264
author Liu, Weiping
Yang, Yong
Qi, Shunan
Wang, Ying
He, Xia
Zhang, Liling
Qu, Baolin
Qian, Liting
Hou, Xiaorong
Qiao, Xueying
Wang, Hua
Li, Gaofeng
Zhang, Yujing
Zhu, Yuan
Cao, Jianzhong
Wu, Junxin
Wu, Tao
Zhu, Suyu
Shi, Mei
Xu, Liming
Su, Hang
Lin, Ningjing
Zhu, Jun
Li, Yexiong
Song, Yuqin
author_facet Liu, Weiping
Yang, Yong
Qi, Shunan
Wang, Ying
He, Xia
Zhang, Liling
Qu, Baolin
Qian, Liting
Hou, Xiaorong
Qiao, Xueying
Wang, Hua
Li, Gaofeng
Zhang, Yujing
Zhu, Yuan
Cao, Jianzhong
Wu, Junxin
Wu, Tao
Zhu, Suyu
Shi, Mei
Xu, Liming
Su, Hang
Lin, Ningjing
Zhu, Jun
Li, Yexiong
Song, Yuqin
author_sort Liu, Weiping
collection PubMed
description Patients with advanced-stage natural killer/T-cell lymphoma (NKTCL) usually have a poor prognosis. However, there is limited data of comprehensive analysis on this particular patient population due to the rarity of the disease. The present study aimed to investigate the treatment models, survival outcomes, and prognosis of advanced-stage NKTCL. Data from 336 patients with advanced-stage NKTCL diagnosed between 2006 and 2015 in the China Lymphoma Collaborative Group database were retrospectively analyzed. The median age was 42 years and the male/female ratio was 2.4:1. About 97% of patients had stage IV disease and 77% had >1 extranodal involvement site. All patients received chemotherapy, with the most common option being asparaginase (Asp)-containing regimens (n=146; 43.5%). Among 286 patients with available response data, the overall response rate (ORR) was 57.3% with a complete remission (CR) rate of 35.7%. Asp-containing regimens led to better ORRs (86/132, 65.2% vs. 54/113, 47.8%, P = 0.006) and CR rates (60/132, 45.5% vs. 27/113, 23.9%, P < 0.001) than non-Asp-containing regimens. The expected 5-year progression-free survival (PFS) and overall survival (OS) rates were 22.6 and 32.0%, respectively, for the whole cohort. Compared to non-Asp-containing chemotherapy, Asp-containing chemotherapy improved 5-year PFS (34.2 vs. 17.1%, P < 0.001) and OS (45.3 vs. 27.8%, P < 0.001). A trend toward improvement in OS was observed when gemcitabine was added to Asp-containing chemotherapies. Moreover, those undergoing autologous hematopoietic stem cell transplantation had prolonged survival time. In conclusion, Asp-containing chemotherapy could improve the prognosis of advanced-stage NKTCL, and refinement of treatment models is warranted in the future.
format Online
Article
Text
id pubmed-7945040
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79450402021-03-11 Treatment, Survival, and Prognosis of Advanced-Stage Natural Killer/T-Cell Lymphoma: An Analysis From the China Lymphoma Collaborative Group Liu, Weiping Yang, Yong Qi, Shunan Wang, Ying He, Xia Zhang, Liling Qu, Baolin Qian, Liting Hou, Xiaorong Qiao, Xueying Wang, Hua Li, Gaofeng Zhang, Yujing Zhu, Yuan Cao, Jianzhong Wu, Junxin Wu, Tao Zhu, Suyu Shi, Mei Xu, Liming Su, Hang Lin, Ningjing Zhu, Jun Li, Yexiong Song, Yuqin Front Oncol Oncology Patients with advanced-stage natural killer/T-cell lymphoma (NKTCL) usually have a poor prognosis. However, there is limited data of comprehensive analysis on this particular patient population due to the rarity of the disease. The present study aimed to investigate the treatment models, survival outcomes, and prognosis of advanced-stage NKTCL. Data from 336 patients with advanced-stage NKTCL diagnosed between 2006 and 2015 in the China Lymphoma Collaborative Group database were retrospectively analyzed. The median age was 42 years and the male/female ratio was 2.4:1. About 97% of patients had stage IV disease and 77% had >1 extranodal involvement site. All patients received chemotherapy, with the most common option being asparaginase (Asp)-containing regimens (n=146; 43.5%). Among 286 patients with available response data, the overall response rate (ORR) was 57.3% with a complete remission (CR) rate of 35.7%. Asp-containing regimens led to better ORRs (86/132, 65.2% vs. 54/113, 47.8%, P = 0.006) and CR rates (60/132, 45.5% vs. 27/113, 23.9%, P < 0.001) than non-Asp-containing regimens. The expected 5-year progression-free survival (PFS) and overall survival (OS) rates were 22.6 and 32.0%, respectively, for the whole cohort. Compared to non-Asp-containing chemotherapy, Asp-containing chemotherapy improved 5-year PFS (34.2 vs. 17.1%, P < 0.001) and OS (45.3 vs. 27.8%, P < 0.001). A trend toward improvement in OS was observed when gemcitabine was added to Asp-containing chemotherapies. Moreover, those undergoing autologous hematopoietic stem cell transplantation had prolonged survival time. In conclusion, Asp-containing chemotherapy could improve the prognosis of advanced-stage NKTCL, and refinement of treatment models is warranted in the future. Frontiers Media S.A. 2021-02-19 /pmc/articles/PMC7945040/ /pubmed/33718104 http://dx.doi.org/10.3389/fonc.2020.583050 Text en Copyright © 2021 Liu, Yang, Qi, Wang, He, Zhang, Qu, Qian, Hou, Qiao, Wang, Li, Zhang, Zhu, Cao, Wu, Wu, Zhu, Shi, Xu, Su, Lin, Zhu, Li and Song http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Liu, Weiping
Yang, Yong
Qi, Shunan
Wang, Ying
He, Xia
Zhang, Liling
Qu, Baolin
Qian, Liting
Hou, Xiaorong
Qiao, Xueying
Wang, Hua
Li, Gaofeng
Zhang, Yujing
Zhu, Yuan
Cao, Jianzhong
Wu, Junxin
Wu, Tao
Zhu, Suyu
Shi, Mei
Xu, Liming
Su, Hang
Lin, Ningjing
Zhu, Jun
Li, Yexiong
Song, Yuqin
Treatment, Survival, and Prognosis of Advanced-Stage Natural Killer/T-Cell Lymphoma: An Analysis From the China Lymphoma Collaborative Group
title Treatment, Survival, and Prognosis of Advanced-Stage Natural Killer/T-Cell Lymphoma: An Analysis From the China Lymphoma Collaborative Group
title_full Treatment, Survival, and Prognosis of Advanced-Stage Natural Killer/T-Cell Lymphoma: An Analysis From the China Lymphoma Collaborative Group
title_fullStr Treatment, Survival, and Prognosis of Advanced-Stage Natural Killer/T-Cell Lymphoma: An Analysis From the China Lymphoma Collaborative Group
title_full_unstemmed Treatment, Survival, and Prognosis of Advanced-Stage Natural Killer/T-Cell Lymphoma: An Analysis From the China Lymphoma Collaborative Group
title_short Treatment, Survival, and Prognosis of Advanced-Stage Natural Killer/T-Cell Lymphoma: An Analysis From the China Lymphoma Collaborative Group
title_sort treatment, survival, and prognosis of advanced-stage natural killer/t-cell lymphoma: an analysis from the china lymphoma collaborative group
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7945040/
https://www.ncbi.nlm.nih.gov/pubmed/33718104
http://dx.doi.org/10.3389/fonc.2020.583050
work_keys_str_mv AT liuweiping treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup
AT yangyong treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup
AT qishunan treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup
AT wangying treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup
AT hexia treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup
AT zhangliling treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup
AT qubaolin treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup
AT qianliting treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup
AT houxiaorong treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup
AT qiaoxueying treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup
AT wanghua treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup
AT ligaofeng treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup
AT zhangyujing treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup
AT zhuyuan treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup
AT caojianzhong treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup
AT wujunxin treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup
AT wutao treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup
AT zhusuyu treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup
AT shimei treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup
AT xuliming treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup
AT suhang treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup
AT linningjing treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup
AT zhujun treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup
AT liyexiong treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup
AT songyuqin treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup